Schools of Pharmacy and Medicine, Creighton University, 2500 California Plaza, Omaha, NE, 68178, USA.
CNS Drugs. 2018 Feb;32(2):149-159. doi: 10.1007/s40263-018-0502-z.
Restless legs syndrome is a common neurological condition affecting a substantial portion of the population. It can be an idiopathic disorder, or one that is secondary to another cause. Given that the underlying pathophysiology of restless legs syndrome is not well understood, several drug classes have been studied for symptom control. While dopamine agonists have long been the mainstay of first-line treatment for restless legs syndrome, recently, the α2δ ligands have been increasingly used. These agents have proven both efficacious and safe in a number of clinical trials. Additionally, compared with the dopamine agonists, they have been associated with less augmentation, a phenomenon whereby symptoms emerge earlier in the day, become more severe, and may spread to areas of the body previously unaffected. Newer clinical guidelines for restless legs syndrome are increasingly recommending the α2δ ligands as a logical first-choice medication for patients needing drug therapy for symptom control.
不宁腿综合征是一种常见的神经系统疾病，影响着相当一部分人群。它可以是特发性疾病，也可以是由其他原因引起的继发性疾病。鉴于不宁腿综合征的潜在病理生理学机制尚未完全清楚，已经研究了几类药物来控制症状。虽然多巴胺激动剂长期以来一直是不宁腿综合征一线治疗的主要药物，但最近，α2δ 配体的应用越来越多。这些药物在多项临床试验中被证明既有效又安全。此外，与多巴胺激动剂相比，它们与较少的增敏现象有关，即症状在一天中出现得更早，变得更严重，并且可能扩散到以前不受影响的身体部位。不宁腿综合征的新临床指南越来越推荐α2δ 配体作为需要药物治疗控制症状的患者的合理首选药物。
